Array Biopharma (ARRY) Reports In-Line Q1 EPS
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $7.24 +1.69%
EPS Growth %: -52.0%
Financial Fact:
Loss from operations: -24M
Today's EPS Names:
STZ, NKE, PRGS, More
EPS Growth %: -52.0%
Financial Fact:
Loss from operations: -24M
Today's EPS Names:
STZ, NKE, PRGS, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q1 EPS of ($0.22), in-line with the analyst estimate of ($0.22). Revenue for the quarter came in at $29.7 million versus the consensus estimate of $33.28 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
- Winnebago Industries (WGO) Misses Q3 EPS by 11c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
